These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 34081085)
21. Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. van Bommel MHD; Steenbeek MP; IntHout J; Hermens RPMG; Hoogerbrugge N; Harmsen MG; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Prins JB; Custers JAE; de Hullu JA Support Care Cancer; 2022 Apr; 30(4):3409-3418. PubMed ID: 34997316 [TBL] [Abstract][Full Text] [Related]
22. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. Bober SL; Recklitis CJ; Bakan J; Garber JE; Patenaude AF J Sex Med; 2015 Jan; 12(1):189-97. PubMed ID: 25311333 [TBL] [Abstract][Full Text] [Related]
23. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives. Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807 [TBL] [Abstract][Full Text] [Related]
24. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
25. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752 [TBL] [Abstract][Full Text] [Related]
26. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845 [TBL] [Abstract][Full Text] [Related]
27. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
28. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis. Wang Y; Song Z; Zhang S; Wang X; Li P Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860 [TBL] [Abstract][Full Text] [Related]
29. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639 [TBL] [Abstract][Full Text] [Related]
30. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy. Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862 [TBL] [Abstract][Full Text] [Related]
31. Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature. Perez L; Webster E; Bull L; Brewer JT; Ahsan MD; Lin J; Levi SR; Cantillo E; Chapman-Davis E; Holcomb K; Rosenberg SM; Frey MK Gynecol Oncol; 2023 Jun; 173():106-113. PubMed ID: 37116391 [TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508 [TBL] [Abstract][Full Text] [Related]
33. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. Solsky I; Chen J; Rebbeck TR Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993 [TBL] [Abstract][Full Text] [Related]
34. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487 [TBL] [Abstract][Full Text] [Related]
35. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study. Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390 [TBL] [Abstract][Full Text] [Related]
36. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer. Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642 [TBL] [Abstract][Full Text] [Related]
37. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. van Driel C; de Bock GH; Schroevers MJ; Mourits MJ BJOG; 2019 Feb; 126(3):402-411. PubMed ID: 30222235 [TBL] [Abstract][Full Text] [Related]
38. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902 [TBL] [Abstract][Full Text] [Related]
39. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420 [TBL] [Abstract][Full Text] [Related]
40. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]